Tags : Humira

Biosimilars

Alvotech Seeks to End the AbbVie’s Wrong Monopoly on Humira

Shots: Alvotech has filed a federal lawsuit to end the monopoly on AbbVie’s Humira for taking several improper steps to inflate its patent portfolio includes multiple patents on the same invention and obtain patents through inequitable conduct Alvotech develops AVT02 as a biosimilar of Humira for chronic pain with equal in strength to Humira’s latest […]Read More

Biosimilars

Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada

Shots: Health Canada has authorized Hyrimoz on Nov 4, 2020 for marketing in Canada. Hyrimoz has been approved for use in all same indications as reference Humira, including rheumatology, gastroenterology and dermatology A patient support program will be available to patients treated with Hyrimoz providing guidance with reimbursement navigation, financial assistance, administrative support & education […]Read More

Top 20

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they […]Read More

Regulatory

AbbVie & Eisai’s Humira (adalimumab) Receives Approval for Hidradenitis Suppurativa

Shots: The approval is based on Japanese P-III study results assessing Humira (adalimumab) in patients with moderate-to-severe HS, evaluating its efficacy and safety The study resulted in meeting its 1EPs as HiSCR @12 wks. in 13/15 patients, ADRs in 6/15 Humira (adalimumab) is an anti-TNF-α mAb approved in Japan for rheumatoid arthritis (RA), plaque psoriasis, […]Read More